Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002649 · ClinicalTrials.gov registry record · Phase 3
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT00002649: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00002649 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002649, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of interleukin-2 with that of observation following radiation therapy, combination chemotherapy, and peripheral stem cell transplantation in treating patients who have refractory or relapsed non-Hodgkin's lymphoma. Interleukin-2 may stimulate a person's white blood cells to kill non-Hodgkin's lymphoma cells. Giving interleukin-2 after radiation therapy, chemotherapy, and peripheral stem cell transplantation may kill more cancer cells
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- RADIATION radiation therapy
- BIOLOGICAL aldesleukin
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 1995-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002649
The ClinicalTrials.gov registry entry for NCT00002649 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002649 about?
NCT00002649 is a clinical study titled "Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma". Randomized phase III trial to compare the effectiveness of interleukin-2 with that of observation following radiation therapy, combination chemotherapy, and peripheral stem cell transplantation in treating patients who have refractory or relapsed non-Hodgkin's lymphoma. Interleukin-2 may stimulate a...
What is the current status of trial NCT00002649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 1995-05.
What interventions are being tested in trial NCT00002649?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), radiation therapy (RADIATION), aldesleukin (BIOLOGICAL), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002649?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.